Blog

27 Articles

Pancreatic cancer patient Matthew Rosenblum, his partner Natalie, and their dog Monique
Survivor Stories
March 15, 2024 • 4 Min

Sometimes Things Get Worse Before They Get Better

Matthew Rosenblum thought his time was limited after a pancreatic cancer diagnosis at age 32, but he’s a BRCA2 carrier, which opened treatment options.

Acinar cell pancreatic cancer patient Paul Suntup
Survivor Stories
December 27, 2023 • 7 Min

A Long Journey That Began With Pancreatitis

Paul Suntup’s diagnosis of acinar cell pancreatic cancer was just the start of a long treatment journey, but he’s still here.

neon lights in the shape of DNA
Research
June 22, 2023 • 2 Min

Targeted Therapy for Cancers Carrying the PALB2 Mutation

Researchers are testing a type of targeted therapy called a PARP inhibitor for cancers carrying the PALB2 mutation.

Grace and Jay Bozick and their horse
Survivor Stories
January 10, 2023 • 4 Min

Taking Chances to Beat Pancreatic Cancer

With a family history of pancreatic cancer, Jay Bozick discovered he carries the BRCA2 mutation, which directed his treatment.

long-term pancreatic cancer survivor Elizabeth O'Connor and her family
Survivor Stories
April 11, 2022 • 6 Min

Cherishing the Simple Things

Elizabeth O’Connor has a PALB2 genetic mutation so her stage IV pancreatic cancer has responded to immunotherapy.

Kim Reiss Binder
Research
January 12, 2022 • 5 Min

New Study Aims to Reduce Recurrence Risk for Select Patients

Dr. Kim A. Reiss is leading a study of the PARP inhibitor olaparib to delay or prevent a recurrence of surgically removed pancreatic cancer.

pancreatic cancer long-term survivor Helene Avraham-Katz and her family
Survivor Stories
September 23, 2021 • 5 Min

The Butterfly Effect and Living Every Day to My Fullest

Because Helene Avraham-Katz has the BRCA2 mutation, certain chemotherapies work better and she is eligible for specific clinical trials.

orange and blue kaleidoscopic pattern
Research
August 11, 2021 • 2 Min

Testing a PARP Inhibitor for Metastatic Pancreatic Cancer Patients with DNA Repair Mutations

Researchers are testing a PARP inhibitor that is effective for cancers in pancreatic cancer patients with DNA repair mutations.

pancreatic cancer patient Chris Treubert
Survivor Stories
May 28, 2021 • 3 Min

BRCA Mutation Determines My Pancreatic Cancer Treatment

Chris Treubert started with one type of chemotherapy but when the results of genetic testing showed a BRCA mutation he changed treatment.

pancreatic cancer patient Irma Infante
Survivor Stories
November 30, 2020 • 4 Min

A Second Opinion Makes the Difference

Irma Infante refused to give up after a stage IV pancreatic cancer diagnosis. She went for a second opinion and better treatment options.

pancreatic cancer patient Harvey Parker and his wife and daughters
Survivor Stories
April 24, 2020 • 5 Min

Genetic Testing Leads Me to a PARP Inhibitor Trial

Harvey Parker had genetic testing as part of his initial pancreatic cancer treatment. The BRCA2 mutation led him to a PARP inhibitor clinical trial.

Pancreatic cancer patient Davi D'Agostino with student paintings on a river cruise ship
Survivor Stories
February 10, 2020 • 5 Min

My Pancreatic Cancer Clinical Trial Journey

After starting pancreatic cancer treatment, Davi D’Agostino discovered she has the BRCA2 mutation, which made her eligible for a clinical trial.

Gloria Peterson, Ph.D.
Research
February 4, 2019 • 5 Min

Genetic Testing for All Pancreatic Cancer Patients

A study by Dr. Gloria Petersen’s research team has led to an official recommendation that all pancreatic cancer patients get genetic testing.

Old medicine bottles
Research
January 22, 2019 • 4 Min

A PARP Inhibitor Approval for Pancreatic Cancer

PARP inhibitors, a type of targeted therapy, are being studied as treatment for pancreatic cancer in a number of clinical trials.

A human epithelial cell (DNA in blue) with increased numbers of centrosomes (green) amid a sea of normal cells.
Research
January 14, 2019 • 2 Min

Combining Immunotherapy and Targeted Therapy for Pancreatic Cancer

Researchers are combining immunotherapy and targeted therapy in a clinical trial for pancreatic cancer patients on platinum-based chemotherapy.

  • 1
  • 2